Criteria for calcimimetic agent in the treatment of more severe secondary hyperparathyroidism.
Pavlovic
D
D
Brzac
H T
HT
D000814:Aniline Compounds / Q000627:therapeutic use*; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000503:physiopathology; D010627:Phenethylamines; D011437:Propylamines; D012720:Severity of Illness Index
D000814:Aniline Compounds; C107873:N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine; D010627:Phenethylamines; D011437:Propylamines